DR. BRUCE JAY BAUM, D.M.D., PH.D.
Dentist in Bethesda, MD
License number
Maryland 6106
Category
Dentist
Type
Dentist
Address
Address
10 Rm. 1N113, Bethesda, MD 20892
Phone
(301) 496-1363
(301) 402-1228 (Fax)
(301) 402-1228 (Fax)
Professional information
Dr. Bruce J Baum, Bethesda MD - DMD (Doctor of Dental Medicine)
Specialties:
Dentistry
Address:
10 Msc-1190 RM 1N113, Bethesda 20892
(301) 496-1363 (Phone), (301) 402-1228 (Fax)
(301) 496-1363 (Phone), (301) 402-1228 (Fax)
Languages:
English
Hybrid Adeno-Retroviral Vector For The Transfection Of Cells
US Patent:
2009025, Oct 15, 2009
Filed:
Jun 19, 2009
Appl. No.:
12/488464
Inventors:
Changyu Zheng - Rockville MD, US
Brian O'Connell - Dublin, IE
Bruce J. Baum - Bethesda MD, US
Brian O'Connell - Dublin, IE
Bruce J. Baum - Bethesda MD, US
International Classification:
A61K 48/00, A61P 43/00
US Classification:
514 44 R
Abstract:
An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention. A pharmaceutical composition is also provided that includes an adenoviral vector of the invention and a pharmaceutically acceptable carrier.
Hybrid Adeno-Retroviral Vector For The Transfection Of Cells
US Patent:
7052904, May 30, 2006
Filed:
Jan 30, 2001
Appl. No.:
10/182644
Inventors:
Changyu Zheng - Rockville MD, US
Brian O'Connell - Co. Dublin, IE
Bruce J. Baum - Bethesda MD, US
Brian O'Connell - Co. Dublin, IE
Bruce J. Baum - Bethesda MD, US
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
C12N 15/861, C12N 15/867, C12N 15/63, A61K 48/00
US Classification:
4353201, 435455, 435456, 424 931, 424 932, 424 936
Abstract:
An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention.
Hybrid Adeno-Retroviral Vector For The Transfection Of Cells
US Patent:
7618623, Nov 17, 2009
Filed:
Oct 19, 2005
Appl. No.:
11/255059
Inventors:
Changyu Zheng - Rockville MD, US
Brian O'Connell - Dublin, IE
Bruce J. Baum - Bethesda MD, US
Brian O'Connell - Dublin, IE
Bruce J. Baum - Bethesda MD, US
Assignee:
The United of States of America as represented by the Secretary of the Department of Health and Human Services - Bethesda MD
International Classification:
A61K 48/00, A01N 63/00, A01N 43/04, A61K 31/711, C12N 15/861, C12N 15/867, C12N 15/33
US Classification:
424 933, 424 931, 424 932, 424 936, 514 44, 435456, 4353201
Abstract:
An adenovirus, including adenoviral capsid proteins, and a replication-defective adenoviral vector that includes a 5′ retroviral LTR nucleic acid sequence, a 3′ retroviral LTR nucleic acid sequence, a nucleic acid sequence encoding a portion of a retroviral envelope protein adjacent to either the 5′ LTR or the 3′ LTR nucleic acid sequence, a retroviral packaging sequence and a nucleic acid sequence encoding a transgene located between the 5′ LTR and the 3′ LTR is provided. Host cells infected with this adenovirus are also provided. An adenoviral vector is provided that includes an adenoviral polynucleotide sequence comprising a nucleic acid encoding a transgene, a retroviral packaging signal, a 5′ and a 3′ retroviral LTR, and a portion of a retroviral envelope polypeptide, wherein the adenoviral polynucleotide sequence does not encode one or more of E1, E3 or E4. A method for transforming a cell is also provided using a virus or a vector of the invention, as is a method for introducing a transgene into a cell that is not able to produce viral particles with a single viral vector. A method is also provided for preventing or treating disorder in a subject using the adenoviral vectors of the invention.
Hybrid Adenoviral Vector
US Patent:
7226779, Jun 5, 2007
Filed:
Jan 25, 2002
Appl. No.:
10/470784
Inventors:
Changyu Zheng - Rockville MD, US
Bruce J. Baum - Bethesda MD, US
Brian C. O'Connell - Dublin, IE
Bruce J. Baum - Bethesda MD, US
Brian C. O'Connell - Dublin, IE
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
C12N 15/00
US Classification:
4353201
Abstract:
An adenoviral vector is disclosed that includes two adenoviral ITRs, wherein the two adenoviral ITRs flank a packaging signal and a single retroviral LTR operably linked to a nucleic acid sequence of interest, wherein the adenoviral vector does not include a nucleic acid sequence encoding the retroviral structural proteins and wherein the adenoviral vector does not include a second retroviral LTR. In one embodiment, a method for transforming a cell is disclosed. In another embodiment, a method is disclosed for introducing a transgene into a cell with a single viral vector. In a further embodiment, a method is provided for preventing or treating disorder in a subject. A pharmaceutical composition is also provided.
Modified Growth Hormone
US Patent:
7271150, Sep 18, 2007
Filed:
May 14, 2002
Appl. No.:
10/477651
Inventors:
Yoke Peng Loh - Bethesda MD, US
Niamh Cawley - Bethesda MD, US
Bruce J. Baum - Bethesda MD, US
Christopher R. Snell - Norfolk, GB
Niamh Cawley - Bethesda MD, US
Bruce J. Baum - Bethesda MD, US
Christopher R. Snell - Norfolk, GB
Assignee:
United States of America, Represented by the Secretary, Department of Health and Human Services - Washington DC
International Classification:
A61K 38/27, C07K 14/61
US Classification:
514 12, 530399
Abstract:
The invention provides a growth hormone (GH) in which amino acids within the regulated secretory pathway (RSP) sorting signal have been mutated as well as a GH in which the three-dimensional conformation of the RSP sorting signal has been altered, and a composition comprising an effective amount of such a GH in an excipient.
Modified Growth Hormone
US Patent:
2011013, Jun 9, 2011
Filed:
Jan 19, 2011
Appl. No.:
13/009414
Inventors:
Yoke Peng Loh - Bethesda MD, US
Niamh Cawley - Bethesda MD, US
Bruce J. Baum - Bethesda MD, US
Christopher R. Snell - Norfolk, GB
Niamh Cawley - Bethesda MD, US
Bruce J. Baum - Bethesda MD, US
Christopher R. Snell - Norfolk, GB
Assignee:
THE UNITED STATES OF AMERICA, REPRESENTED BY, DEPA RTMENT OF HEALTH - BETHESDA MD
International Classification:
A61K 35/12, A61K 48/00, C07K 14/61, C07H 21/00, A61P 5/06, C07H 1/00, C07K 1/107
US Classification:
424 9321, 514 44 R, 530397, 536 2351
Abstract:
The invention provides, a nucleic acid molecule encoding a growth hormone (GH) in which the RSP sorting signal has been mutated, such that the GH can be constitutively secreted by the nonregulated secretory pathway (NRSP) in a mammalian cell. The invention also provides a nucleic acid molecule encoding a GH in which the three-dimensional conformation of the RSP sorting signal has been altered such that the GH can be constitutively secreted by the NRSP in a mammalian cell.
Nucleic Acids Encoding Growth Hormone With A Modified Rsp Sorting Signal
US Patent:
7888070, Feb 15, 2011
Filed:
Sep 6, 2007
Appl. No.:
11/850947
Inventors:
Yoke Peng Loh - Bethesda MD, US
Niamh Cawley - Bethesda MD, US
Bruce J. Baum - Bethesda MD, US
Christopher R. Snell - Norfolk, GB
Niamh Cawley - Bethesda MD, US
Bruce J. Baum - Bethesda MD, US
Christopher R. Snell - Norfolk, GB
Assignee:
The United States of America as represented by the Secretary of the Department of Health and Human Services - Washington DC
International Classification:
C07H 21/04, C12N 5/16, C12N 15/18, C12N 15/63
US Classification:
435 694, 4353201, 435325, 536 2351
Abstract:
The invention provides a nucleic acid molecule encoding a growth hormone (GH) in which the RSP sorting signal has been mutated, such that the GH can be constitutively secreted by the nonregulated secretory pathway (NRSP) in a mammalian cell. The invention also provides a nucleic acid molecule encoding a GH in which the three-dimensional conformation of the RSP sorting signal has been altered such that the GH can be constitutively secreted by the NRSP in a mammalian cell.
Artificial Salivary Gland
US Patent:
2003003, Feb 13, 2003
Filed:
Aug 23, 2001
Appl. No.:
09/938706
Inventors:
Bruce Baum - Bethesda MD, US
Kenneth Yamada - Bethesda MD, US
Edna Cukierman - Rockville MD, US
David Mooney - Ann Arbor MI, US
Kenneth Yamada - Bethesda MD, US
Edna Cukierman - Rockville MD, US
David Mooney - Ann Arbor MI, US
International Classification:
A61K045/00
US Classification:
424/423000, 424/093700
Abstract:
The present invention generally relates to the field of oral prosthetics and tissue engineering. More specifically, a novel, artificial fluid secreting prosthesis for non-invasive insertion is disclosed. Further, methods of use of the foregoing are provided.